RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2009; 134(15): 759-762
DOI: 10.1055/s-0029-1220227
DOI: 10.1055/s-0029-1220227
Prinzip & Perspektive | Review article
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York
Direkte Renininhibition: ein neues und viel versprechendes Wirkprinzip in der Herzinsuffizienztherapie?
Direct renin inhibition: a new and promising treatment principle in heart failure?Weitere Informationen
Publikationsverlauf
eingereicht: 26.11.2008
akzeptiert: 15.1.2009
Publikationsdatum:
01. April 2009 (online)
Schlüsselwörter
Renininhibition - Herzinsuffizienz - Aliskiren
Keywords
renin inhibition - heart failure - aliskiren
Literatur
- 1 Alderman M H, Madhavan S, Ooi W L, Cohen H, Sealey J E, Laragh J H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991; 324 1098-1104
- 2 Brown M J. Aliskiren. Circulation. 2008; 118 773-784
- 3 Burnier M, Brunner H R. Angiotensin II receptor antagonists. Lancet. 2000; 355 637-645
- 4 Mueller D N, Luft F C. Renin receptor blockade: a better strategy for renal protection than Renin-Angiotensin system inhibition?. Current Hypertension Rep. 2008; 10 405-409
- 5 Latini R, Masson S, Anand I. et al . The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25 292-299
- 6 Luft F C. Renin and its putative receptor remain enigmas. J Am Soc Nephrol. 2007; 18 1989-1892
- 7 McMurray J, Bertram P, Latini R. et al . Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation Heart Failure. 2008; 1 17-24
- 8 Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002; 109 1417-1427
- 9 Parving H H, Persson F, Lewis J B, Lewis E J, Hollenberg N K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358 2433-2446
- 10 Parving H H, Lewis J B, Lewis E J, Hollenberg N K. AVOID Aliskiren in the Evaluation of Proteinuria in Diabetes. California, USA; American Society of Nephrology Renal Week Congress in San Francisco 2007 Poster SA-P01051
- 11 Pfeffer M A, McMurray J J, Velazquez E J. et al . Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349 1893-1906
- 12 Skeggs L T, Kahn J R, Lentz K, Shumway N P. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957; 106 439-453
- 13 Solomen S D, Appelbaum E, Manning W. et al . Effect o fthe direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009; 119 530-537
- 14 Staessen J A, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006; 368 1449-1456
- 15 Werner C, Baumhakel M, Teo K K. et al . RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008; 97 418-431
Dr. med. Felix Mahfoud
Klinik für Innere Medizin III, Kardiologie,
Angiologie und Internistische Intensivmedizin
Kirrberger
Straße
66421 Homburg/Saar
Telefon: 06841/16-23000
Fax: 06841/16-23389
eMail: felix.mahfoud@uks.eu